Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967437 | 0.88 | MAPT (0.65) | MAPTCYP3A4CYP19A1KMT2AHSP90AA1 | |
| SCHEMBL11366095 | 0.80 | MAPT (0.77) | MAPTCYP3A4CYP19A1KMT2AHSP90AA1 | |
| SCHEMBL2192813 | 0.78 | KMT2A (0.50) | MAPTCYP19A1KMT2AHSP90AA1MEN1 | |
| SCHEMBL1966676 | 0.78 | MAPT (0.54) | MAPTCYP3A4CYP19A1KMT2AHSP90AA1 | |
| SCHEMBL2215950 | 0.78 | MAPT (0.51) | MAPTCYP3A4CYP19A1KMT2AHSP90AA1 | |
| SCHEMBL2169975 | 0.78 | MAPT (0.51) | MAPTCYP3A4CYP19A1KMT2AHSP90AA1 | |
| SCHEMBL11641005 | 0.78 | MAPT (0.56) | MAPTCYP3A4CYP19A1KMT2AHSP90AA1 | |
| SCHEMBL12418531 | 0.78 | MAPT (0.58) | MAPTCYP3A4KMT2AHSP90AA1MEN1 | |
| SCHEMBL10666615 | 0.76 | MAPT (0.55) | MAPTCYP3A4CYP19A1KMT2AMEN1 | |
| SCHEMBL1923770 | 0.75 | MAPT (0.55) | MAPTCYP3A4KMT2AHSP90AA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172097-A1 | Imidazole and Triazole Compounds, Their Use and Agents Containing The Same | BASF SE (DE) | 2011-07-14 | — | — | US | disclosed |
| EP-2334650-A1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS, THEIR USE AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010031848-A1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS, THEIR USE AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172097-A1 | Imidazole and Triazole Compounds, Their Use and Agents Containing The Same | COX4I1, CYP2C19, CYP3A43 | MAPT 513/4885CYP3A4 4/4885CYP19A1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.